Daratumumab Plus Bortezomib, Lenalidomide, and Dexamethasone in Newly Diagnosed Multiple Myeloma: Transplant-Ineligible Subgroup Analysis of CEPHEUS
- DOI
- 10.1200/jco-26-00401
- Published
- 2026-09-25
- Container
- Journal of Clinical Oncology
- Publisher
- American Society of Clinical Oncology (ASCO)
- Open access
- unknown
Credibility signals
uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- supportingDOI registered: A matching record was returned by Crossref.
- supportingDOI resolves: A matching record was returned by Crossref.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- supportingMetadata completeness: All 6 scored descriptive metadata groups are present.
Cite this work
BibTeX
@article{allodium:10.1200/jco-26-00401,
title = {Daratumumab Plus Bortezomib, Lenalidomide, and Dexamethasone in Newly Diagnosed Multiple Myeloma: Transplant-Ineligible Subgroup Analysis of CEPHEUS},
author = {Saad Z. Usmani and Thierry Facon and Vania Hungria and Nizar J. Bahlis and Christopher P. Venner and Marc Braunstein and Ludek Pour and Josep M. Marti and Supratik Basu and Yael C. Cohen and Morio Matsumoto and Kenshi Suzuki and Cyrille Hulin and Sebastian Grosicki and Wojciech Legiec and Meral Beksac and Angelo Maiolino and Hiroyuki Takamatsu and Aurore Perrot and Mehmet Turgut and Weiping Liu and Jianping Wang and Maria Krevvata and Jaclyn Stanziola and Matteo Loi and Emilie M.J. Van Brummelen and Lorena Lopez-Masi and Melissa Rowe and Robin L. Carson and Sonja Zweegman},
year = {2026},
journal = {Journal of Clinical Oncology},
doi = {10.1200/jco-26-00401},
url = {https://doi.org/10.1200/jco-26-00401}
}RIS
TY - JOUR TI - Daratumumab Plus Bortezomib, Lenalidomide, and Dexamethasone in Newly Diagnosed Multiple Myeloma: Transplant-Ineligible Subgroup Analysis of CEPHEUS AU - Saad Z. Usmani AU - Thierry Facon AU - Vania Hungria AU - Nizar J. Bahlis AU - Christopher P. Venner AU - Marc Braunstein AU - Ludek Pour AU - Josep M. Marti AU - Supratik Basu AU - Yael C. Cohen AU - Morio Matsumoto AU - Kenshi Suzuki AU - Cyrille Hulin AU - Sebastian Grosicki AU - Wojciech Legiec AU - Meral Beksac AU - Angelo Maiolino AU - Hiroyuki Takamatsu AU - Aurore Perrot AU - Mehmet Turgut AU - Weiping Liu AU - Jianping Wang AU - Maria Krevvata AU - Jaclyn Stanziola AU - Matteo Loi AU - Emilie M.J. Van Brummelen AU - Lorena Lopez-Masi AU - Melissa Rowe AU - Robin L. Carson AU - Sonja Zweegman PY - 2026 JO - Journal of Clinical Oncology DO - 10.1200/jco-26-00401 UR - https://doi.org/10.1200/jco-26-00401 ER -
APA
Usmani, S. Z., Facon, T., Hungria, V., Bahlis, N. J., Venner, C. P., Braunstein, M., Pour, L., Marti, J. M., Basu, S., Cohen, Y. C., Matsumoto, M., Suzuki, K., Hulin, C., Grosicki, S., Legiec, W., Beksac, M., Maiolino, A., Takamatsu, H., Perrot, A., Turgut, M., Liu, W., Wang, J., Krevvata, M., Stanziola, J., Loi, M., Brummelen, E. M. V., Lopez-Masi, L., Rowe, M., Carson, R. L., & Zweegman, S. (2026). Daratumumab Plus Bortezomib, Lenalidomide, and Dexamethasone in Newly Diagnosed Multiple Myeloma: Transplant-Ineligible Subgroup Analysis of CEPHEUS. Journal of Clinical Oncology. https://doi.org/10.1200/jco-26-00401
Source records
- crossref · retrieved 2026-11-08T21:30:28.191Z